The FDA had a busy first half of 2023 with 28 novel drug approvals thus far. Follow along with BioSpace as the regulator embarks on on what could be a momentous second half.
The FDA had a busy first half of 2023 with 28 novel drug approvals thus far. Follow along with BioSpace as the regulator embarks on on what could be a momentous second half.